COGNITION THERAPEUTICS INC Stock Price, News & Analysis

Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced that its president and CEO, Lisa Ricciardi, will present at the Oppenheimer & Co Healthcare Conference occurring virtually from March 13-15, 2023. Ricciardi's presentation is scheduled for March 15, 2023, at 10:00 a.m. ET, where she will discuss the company's pipeline progress, recent achievements, and future milestones. Interested investors can access the live webcast and subsequent archived replay via the company’s investor site. Cognition Therapeutics focuses on developing therapeutics targeting age-related degenerative disorders, particularly through its lead candidate CT1812 aimed at treating Alzheimer’s disease and other related conditions.

Cognition Therapeutics (CGTX) has received FDA clearance to commence its 540-patient Phase 2 START study of CT1812 for early Alzheimer's disease. This innovative oral small molecule aims to block toxic beta amyloid effects on neurons. The study will be conducted at 50-60 North American sites and is backed by an $81 million NIH grant over five years. Initial results of CT1812 have been encouraging, and further investigation is expected to enhance treatment options for Alzheimer's. The trial will evaluate CT1812's efficacy and safety over 18 months against placebo, utilizing established cognitive assessment tools.

Cognition Therapeutics, Inc. (Nasdaq: CGTX) has launched its third podcast episode focused on Lewy body dementia, featuring caregivers who share their experiences and insights. The podcast, moderated by CEO Lisa Ricciardi, highlights key symptoms, preparation for doctor visits, and the challenges faced by caregivers. Lewy body dementias, affecting approximately 1.4 million Americans, include Parkinson’s disease dementia and dementia with Lewy bodies, sharing symptoms such as cognitive impairment and visual hallucinations. The company is conducting a Phase 2 SHIMMER trial for its candidate CT1812, with support from a $30M NIH grant.

Cognition Therapeutics (Nasdaq: CGTX) has completed enrollment for its Phase 2 SEQUEL study (COG0202) involving 16 adults with mild-to-moderate Alzheimer’s disease. This randomized, double-blind study aims to investigate the effects of CT1812 using quantitative electroencephalogram (qEEG) to measure changes in theta wave activity, which is linked to memory and information processing. Topline results are expected in mid-2023. The study is supported by a $5.3 million grant from the National Institute of Aging. CT1812 targets sigma-2 receptors to disrupt Aβ oligomers, potentially offering a novel approach to treat Alzheimer's disease.

Cognition Therapeutics (CGTX) recently released its second "Conversations" video podcast featuring experts discussing clinical data from the 2022 CTAD conference. The episode, moderated by Anthony Caggiano, M.D., focuses on insights from the lecanemab CLARITY study, emphasizing the importance of targeting amyloid oligomers for Alzheimer’s treatment. Cognition is advancing its lead candidate CT1812, targeting Alzheimer’s and related disorders, highlighting the necessity of innovative therapeutic approaches in neurodegenerative disease management.

Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced participation in the 6th Annual Sachs Neuroscience Forum, Biotech Showcase, and BIO Partnering at JPM, taking place alongside the J.P. Morgan Annual Healthcare Conference 2023.

The events will feature panel discussions and corporate presentations on Alzheimer's and cognitive disorders, scheduled for January 8-9, 2023, in San Francisco, CA. The Cognition management team will meet with investors and pharmaceutical companies to discuss corporate achievements and clinical development strategies.

Cognition Therapeutics announced the expansion of its Phase 2 SHINE clinical trial for CT1812, an experimental Alzheimer's treatment, to include sites in Spain, the Netherlands, and the Czech Republic, in addition to the USA. The trial aims to enroll 144 participants and investigates CT1812's ability to prevent synaptotoxic effects caused by oligomers. Initial trials indicate potential cognition improvements and brain volume preservation. The study receives approximately $30 million in grant funding from the National Institutes on Aging.

Cognition Therapeutics (Nasdaq: CGTX) announced significant advancements regarding its Phase 2 trial for CT1812, targeting geographic atrophy due to dry age-related macular degeneration (dry AMD). With dry AMD affecting 10 million people in the U.S., the company emphasizes the need for effective treatments. CT1812, an oral sigma-2 receptor modulator, has shown promise in preclinical studies, demonstrating potential to rescue retinal pigment epithelial (RPE) functions impaired by oxidative stress. Cognition is in discussions with the FDA to initiate trials involving over 200 participants.

Cognition Therapeutics has announced the activation of up to 30 sites across the USA for its ongoing SHIMMER clinical trial evaluating CT1812, a novel treatment for dementia with Lewy bodies (DLB). This Phase 2 study aims to assess the safety and efficacy of CT1812, enrolling around 120 adults over six months. DLB currently lacks approved treatments, affecting approximately 1.4 million people in the U.S. The trial is supported by a $30 million grant from the National Institute on Aging and aims to provide crucial insights into cognitive and physical activity changes in DLB patients.